



March 3, 2016

## **Biocept to Present at Molecular Medicine Tri-Con 2016**

### **Presentation to focus on Biocept's unique, patented technology to capture a broad range of CTCs leading to clinical applications and utility**

SAN DIEGO, March 3, 2016 /PRNewswire/ -- [Biocept](#), Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that Veena Singh, MD, Biocept's Senior Vice President and Senior Medical Director, will present "Ultra-Sensitive CTC Analysis in the Management of Cancer" on Monday, March 7<sup>th</sup>, and will participate in a panel discussion focused on the use of circulating tumor cell (CTC) in liquid biopsy on Wednesday, March 9<sup>th</sup>, at the Molecular Medicine Tri-Con 2016 meeting being held in San Francisco.



"First generation CTC detection systems were designed to capture only cells expressing an antigen found on epithelial tumor cells, known as EpCAM. These approaches miss non-EpCAM expressing types of tumor cells, such as those with mesenchymal or stem cell properties, that can contain important tumor related information," said Dr. Singh. "At Biocept, we have developed a highly sensitive approach that can detect a broader spectrum of CTCs and simultaneously identify actionable biomarker alterations within these cells. Our assays detect results that could be missed by relying solely on interrogating a subset of CTCs and provide additional information that physicians can use when making treatment decisions.

"The proprietary platforms we have developed at Biocept allows for liquid biopsy assays that utilize both CTCs and circulating tumor DNA (ctDNA) for both profiling and monitoring patients with solid tumors," continued Dr. Singh. "We appreciate the opportunity to share progress and evidence from our real-world experience with scientific leaders attending this prestigious industry conference. Much of this conference is dedicated to liquid biopsy, which indicates a growing level of interest in our field among researchers, clinicians and the biopharma industry in general."

### **About the Molecular Medicine Tri-Con**

The 23<sup>rd</sup> Annual Molecular Medicine Tri-Con conference is a diverse event, focusing on molecular medicine, specifically on discovery, genomics, diagnostics and information technology. The Tri-Conference is the largest annual conference bringing together the world's most influential diagnostic experts. This year's conference is projected to attract more than 3,300 diagnostics experts from more than 40 countries. The conference will be held March 6-11, 2016, at the Moscone North Convention Center in San Francisco. To learn more, visit <http://www.triconference.com>.

### **About Biocept**

[Biocept](#), Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept's technology platform captures and analyzes circulating tumor DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers testing for gastric, breast, prostate, colon and lung cancers as well as melanoma and plans to introduce CLIA-validated tests for colorectal cancer, prostate cancer and other solid tumors in the near term.

### **Forward-Looking Statements Disclaimer Statement**

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number

of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to the potential of our diagnostic assays to improve the detection and treatment of cancer, the growing level of interest in liquid biopsy, and our ability to introduce CLIA-validated tests in the future, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at [www.sec.gov](http://www.sec.gov).

Logo - <http://photos.prnewswire.com/prnh/20151013/276540LOGO>

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/biocept-to-present-at-molecular-medicine-tri-con-2016-300229654.html>

SOURCE Biocept, Inc.

News Provided by Acquire Media